Cambrex invests $5 million in new laboratory expansion at its Karlskoga, Sweden facility

1 Jun 2018

Money to be spent on augmenting capability and capacity for process development and scale up, handling of potent substances, crystallization studies and solid phase characterization.

Cambrex is to commence a $5 million expansion of laboratory facilities at its Karlskoga, Sweden site, to augment capability and capacity for process development and scale up, handling of potent substances, crystallization studies and solid phase characterization. Construction work on the three storey, 600-m2 building will commence at the end of Q2 2018, with completion due in Q2 2019.

Cambrex invests $5 million in new laboratory expansion at its Karlskoga, Sweden facility

The expansion will create space for a new technical laboratory with walk-in hoods for large scale laboratory syntheses up to 10 L, where engineers and chemists will undertake tech transfer studies. The new investment will also enable handling of potent substances at a large laboratory scale, high pressure reactions and parallel synthesis for API route scouting and development.

In addition to the technical laboratory, the expansion will feature two analytical development and quality control laboratories and additional office space for 12 additional scientists and chemists, taking the total headcount to 60.

“We have a rich history in chemistry at our Karlskoga site, dating back 120 years to Alfred Nobel himself in 1896,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga. He added: “The new laboratory expansion will enhance our ability to provide global customers with scientific and chemical excellence.”

In 2017 Cambrex announced that it had upgraded its continuous flow capabilities in Karlskoga with a dedicated commercial-scale unit, capable of producing multiple metric tons of high purity API intermediates per annum. To complement these capabilities, the company also completed the installation of multiple continuous flow reactor platforms at its process development facility in High Point, North Carolina. This investment is focused on the rapid and successful development of processes to supply clinical as well as commercial demand for chemical syntheses.

Read More

Companies mentioned

Related tags

Market News

Related news

Compact serialization-ready manual workstation

Compact serialization-ready manual workstation

11 Aug 2018

A cost-effective and space-saving solution for serializing cartons and performing multi-level aggregation on cases and pallets.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
BASF receives award for its portfolio of natural cosmetic ingredients

BASF receives award for its portfolio of natural cosmetic ingredients

7 Aug 2018

Company recognised for its innovation and continual delivery of new natural ingredients.

Read more 
Extended distribution agreement enables customers to continuously improve their bioprocesses

Extended distribution agreement enables customers to continuously improve their bioprocesses

6 Aug 2018

Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

3 Aug 2018

The plant will be first-of-its-kind in the US.

Read more 
Croda invests in SiSaf’s novel bio-courier technology

Croda invests in SiSaf’s novel bio-courier technology

3 Aug 2018

ProSilic will give Croda’s customers access to the next generation of targeted and controlled drug delivery.

Read more 
Breast cancer device receives FDA approval

Breast cancer device receives FDA approval

3 Aug 2018

The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.

Read more 
Building contingency plans for an ambiguous post-Brexit market

Building contingency plans for an ambiguous post-Brexit market

31 Jul 2018

One company's positive approach to Brexit preparations, despite the lack of definition.

Read more 
Cherwell publishes guide on environmental monitoring processes and validation

Cherwell publishes guide on environmental monitoring processes and validation

31 Jul 2018

Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.

Read more